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Abstract
Amyloid b (Ab) peptides are proteolytic products from amyloid precursor protein (APP) and are thought to play a role in
Alzheimer disease (AD) pathogenesis. While much is known about molecular mechanisms underlying cerebral Ab
accumulation in familial AD, less is known about the cause(s) of brain amyloidosis in sporadic disease. Animal and postmortem
studies suggest that Ab secretion can be up-regulated in response to hypoxia. We employed a new technology (Single
Molecule Arrays, SiMoA) capable of ultrasensitive protein measurements and developed a novel assay to look for changes in
serum Ab42 concentration in 25 resuscitated patients with severe hypoxia due to cardiac arrest. After a lag period of 10 or
more hours,very clearserumAb42elevationswereobserved inallpatients. Elevationsranged from approximately 80% toover
70-fold, with most elevations in the range of 3–10-fold (average approximately 7-fold). The magnitude of the increase
correlated with clinical outcome. These data provide the first direct evidence in living humans that ischemia acutely increases
Ab levels in blood. The results point to the possibility that hypoxia may play a role in the amyloidogenic process of AD.
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Introduction
Amyloid b (Ab) peptides are produced by many cell types in the
body but the expression is particularly high in the brain.
Accumulation of Ab in the form of extracellular plaques is a
neuropathological hallmark of Alzheimer disease (AD) and thought
toplayacentral roleinthe neurodegenerativeprocess[1].Infamilial
AD, brain amyloidosis is caused by mutations in the genes encoding
amyloid precursor protein (APP) or c-secretase; the enzyme complex
that together with b-secretase is responsible for producing Ab from
APP [2]. However, very little is known about what drives Ab
accumulation in the brains of patients with sporadic AD.
Mounting evidence suggest that cerebral hypoxia may play a role
in the pathogenesis of sporadic AD. Epidemiological data show that
cerebrovascular risk factors, such as hypertension, hyperhomocys-
teinemiaandhypercholesterolemia,increasetheriskofAD[3,4,5,6].
Mild transient brain hypoperfusion in AD transgenic mice results in
an acute increase in Ab secretion through induced b-secretase
(BACE1) protein expression [7], which is regulated by hypoxia
inducible factor 1-a (HIF1-a) [8]. In a similar manner, bilateral
carotid occlusion in rats results in time-dependent accumulation of
oligomeric Ab in the hippocampus [9]. In humans, a marked
increase in Ab expression, peaking at 4 days post-stroke, is found in
pyramidal neurons in the hippocampus of patients who died from
ischemic stroke[10].Finally, a neuropathologicalstudyshowsthatin
patients resuscitated after cardiac arrest who died 3–36 days later,
APP over-expression is found in cortical and subcortical neurons
together with non-fibrillar Ab plaques in the neuropil [11].
To further elucidate the link between hypoxia and Ab
production in living humans, we employed a new technology
(Single Molecule Arrays, SiMoA) capable of ultrasensitive protein
measurements [12,13] to look for changes in serum Ab42
concentration in serial blood samples from patients following
cardiac arrest and resuscitation.
Methods
Ethics statement
The study was performed at the general intensive care unit at
Uppsala University Hospital, Sweden, and approved by the
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28263Human Ethics Committee of Uppsala, Sweden. Written consent
for participation was obtained from a legal next of kin, and later
from survivors, when considered competent.
Patients
Twenty-five unconscious patients(8 women, 17 men, age range 25–
85 years, mean 62 years) with cardiac arrest were resuscitated with
restoration of spontaneous circulation (ROSC). Patients exhibited
systolic blood pressure .80 mmHg after ROSC and a Glasgow
Coma Scale #7. Hypothermia treatment to a body temperature of
32–34uC for 24 hours, ventilation, and pharmacologic support were
administered immediately after resuscitation as described [14]. All
patients received an arterial line in the radial or femoral artery for
blood sampling. Serial blood samples were collected, starting as soon
as possible in the emergency phase (within 6 h after cardiac arrest),
and continuing at 1, 2, 6, 12, 24, 48, 72, 96, and 108 h after cardiac
arrest. Serum aliquots were frozen at 270uC until analysis.
Patient outcome was assessed using the Glasgow-Pittsburgh
cerebral performance category (CPC) scale at discharge from the
intensive care unit and 6 months later [15]. The CPC scale ranges
from 1 to 5, with 1 representing mildest possible neurological
deficit (patient is able to return to work), and 4–5 representing the
most severe deficit (vegetative) and death. A CPC of 1 or 2 was
considered a good outcome and a CPC score of 3–5 a poor
outcome, as described [14]. For patients who died after discharge
from the ICU, the better of the two scores was used, as
recommended by the Utstein templates [16].
Arrays
Patient serum samples were measured in triplicate by a novel
SiMoA Ab42 assay. The technique involves performing a
paramagnetic bead-based ELISA, followed by isolation of
individual capture beads in arrays of femtoliter-sized reaction
wells [13]. Fifty femtoliter reaction wells were prepared as
Figure 1. Assay characteristics. Arrays of femtoliter-volume wells permit isolation of 2.7 mm capture beads from a standard bead-based ELISA
(A), enabling exquisite sensitivity to enzyme label by preventing fluorescent product from diffusing away into a bulk solution. At very low
concentrations of Ab42, beads contain either a single labeled immunocomplex or no complexes, giving rise to digital signal output corresponding to
single molecules (B). Simultaneous counting of active wells across an array statistically powers estimates of average enzymes/bead. (C) Dose-
response of digital immunoassay for Ab42 (n=3). Y-axis refers to average number of enzyme labels per individual microbead captured in the array.
The concentration of label is reduced relative to standard immunoassays, resulting in improved signal:background at very low Ab42 concentration.
Assay calibrators were purified Ab42 (Merck) in PBS/BSA. (C inset) Limit of quantification (LoQ) was estimated from total coefficients of variation (CV)
from five low panel members (spiked PBS/BSA panels, grey circles, and immunodepleted plasma, black circles) assayed repeatedly across five days.
The Ab42 concentration at which total assay imprecision reached 20% (LoQ) was 0.032 pg/mL. (D) Recovery at extremely low Ab42 concentrations
was tested by diluting spiked immunodepleted plasma with PBS/BSA zero calibrator (n=3). Because samples are pre-diluted 4-fold prior to assay to
reduce matrix effects, dilutions include an initial 4-fold dilution.
doi:10.1371/journal.pone.0028263.g001
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28263Figure 2. Serum Ab42 following resuscitation from cardiac arrest. CPC scores depicted are after discharge from the ICU and 6 months later.
Panels on left (A–C) are profiles from patients exhibiting good outcomes, panels on the right (D–F) are from patients with poor outcome. (E)
Illustration of Ab42 profile analysis. Baseline Ab42 was defined as the mean of the two lowest values in the initial 12 hours. The time of initial
elevation was defined as the intersection between the baseline Ab42 and the line of maximum ascension of the major elevation peak. The duration of
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polished, and one end of each bundle was etched in mild acid
solution. Differential etch rates of the optical fiber core and
cladding glass of the bundles caused 4.5 mm diameter, 3.5 mm
deep wells to be formed, giving arrays of microwells across the
bundles. Arrays were mounted in linear groups of eight within
glass holders, spaced to correspond with microtiter plate well
columns that served as rinse troughs following bead loading.
Reagents
Paramagnetic carboxy beads (2.7 mm, Varian) were coated with
a commercially available monoclonal (Covance 6E10) directed to
the N-terminus of Ab42, and diluted to 5610
6 beads/mL in Tris-
BSA. Biotinylated detector was a commercially available mono-
clonal (Invitrogen H31L21) directed to the C-terminus, diluted to
0.1 mg/ml in PBS with newborn calf serum, NCS (PBS/NCS).
Reporter streptavidin:b-galactosidase (SbG) was a conjugate of
purified streptavidin (Thermo Scientific) and bG (Sigma), diluted
to 25 pM in PBS/NCS with 1 mM MgCl2.
ELISA and imaging
Bead-sample incubations and immunocomplex labeling were
conducted in conical 96 well plates (Axygen) in three steps, starting
with analyte capture, incubation with biotinylated detector, and
labeling with SbG. Beads from the ELISA were loaded into
microwells by centrifugation at 1,300 g for 10 minutes. Wells
Table 1. Characteristics of serum Ab42 elevation profiles from resuscitated survivors of cardiac arrest during the first 96–108 hours
following admission to the intensive care unit.
Patient
Magnitude of rise (pg/
mL) Duration of rise (hr)
Rise ratios (fold
increase) Max slope (pg/mL/hr) Ab42 score
Good Poor Good Poor Good Poor Good Poor Good Poor
1 17.4 4.10 0.621
2 6.90 60 70.0 0.150 137
3 11.3 28 4.10 0.315 43.7
4 11.9 25 4.30 0.466 41.7
5 4.60 63 5.60 0.242 73.4
6 8.60 78 9.60 0.110 96.3
7 5.07 32 6.45 0.159 43.7
8 7.10 21 2.45 0.592 31.1
9 9.20 14 6.75 0.657 30.6
10 14.0 66 8.00 0.340 88.3
11 9.50 15 1.81 0.633 26.9
12 26.7 18 5.45 1.48 51.6
13 6.50 28 14.0 0.232 48.7
14 11.0 55 6.50 0.202 72.7
15 11.0 31 4.90 0.360 47.3
16 13.3 3.00 0.887
17 7.20 13 3.13 0.554 23.9
18 6.90 31 2.97 0.276 41.1
19 8.80 3.20 0.587
20 12.3 56 8.70 0.273 77.3
21 9.50 72 16.8 0.132 98.4
22 7.10 31.7 0.372
23 14.7 33 8.00 0.445 56.1
24 7.90 61 4.30 0.282 73.5
25 7.20 72 15.4 0.141 94.7
Mean 8.96 11.1 27.2 54.6 5.49 13.1 0.385 0.444 42.0 79.8
P value 0.137 0.00091 0.095 0.322 0.00056
Parameters were sorted on the basis of good or poor 6-month outcome. Blood sampling was terminated early for patients 1, 16, 19 and 22 for medical reasons, and rise
durations could not be estimated for these patients. The Ab42 score equals the sum of magnitude of rise, duration of rise, rise ratio and max slope.
doi:10.1371/journal.pone.0028263.t001
the Ab42 increase was defined as the difference between time of initial elevation and time beyond which no significant further rise was observed.
The magnitude and maximum slope of rise are also indicated. (A) Patient exhibiting smallest relative increase in Ab42 among all patients. For
confirmation, the sample set was re-assayed on a different day. (D) Patient with poor outcome exhibiting the largest relative increase from baseline.
(C and F) Patients with similar baseline Ab42 and poor cerebral outcome upon discharge from the ICU. Six months later, patient BE had recovered
good cerebral function, while patient LP had not. Error bars: standard deviation of triplicate measurements.
doi:10.1371/journal.pone.0028263.g002
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hydrolysis of enzyme substrate (resorufin b-D-galactopyranoside,
RGP, Invitrogen) by bG into fluorescent product. RGP was
introduced to the wells during array sealing just prior to imaging.
Enzyme-containing wells were imaged by fluorescence microscope
fitted with a CCD camera. The images were analyzed to
determine the average number of label enzymes/bead (AEB) [13].
Statistics
Ab42 levels and changes were compared between outcome
groups using unpaired t-tests in GraphPad Prism 5 (GraphPad
Software Inc., La Jolla, USA).
Results
Singulation of capture beads within microwells permits buildup
of fluorescent product from a single enzyme label, making the
signal from a single immunocomplex readily detectable
(Figure 1A–B). The novel Ab42 assay has a dynamic range to
250 pg/mL (Figure 1C), with limit of quantification of less than
0.04 pg/mL, enabling precise measurement of low abundance
serum Ab42 in all samples. Precise quantification of peripheral
Ab42 to subpicogram levels has not been previously possible with
conventional assay methods. The extreme sensitivity of the assay
also permits pre-dilution of the samples, reducing endogenous
interferences that have been problematic with assays for this
peptide (Figure 1D).
Figure 2 depicts representative elevation profiles for patients
with good and poor 6-month outcomes. Profile parameters were:
magnitude of Ab42 rise, ratio of the peak to baseline Ab42, slope
of Ab42 rise, and the duration over which the Ab42 exhibited
rising values (Figure 2E). The sum (Ab42 score) of these
parameters was also examined (Table 1). All patients were found
to exhibit a significant time-dependent elevation of serum Ab42.
Generally, after a lag period of 10 or more hours, very clear Ab42
elevations were observed. Elevations ranged from approximately
80% to over 70-fold, with most elevations in the range of 3–10-fold
(average approximately 7-fold).
Ab42 profile characteristics for each patient are given in
Table 1, and graphed in Figure 3. There was no relationship
between baseline Ab42 and outcome (p=0.53). Large increases in
Ab42, as reflected by rise magnitudes and ratios, exhibited
marginal association with poor outcome (student t-test p=0.137,
0.095 respectively), while a long duration of rise was associated
with poor outcome (p,0.001). Slope and total area under the
curve (AUC) were not significant (p=0.32, 0.16 respectively, later
not shown). Weak association between AUC and outcome could
be due to incomplete expression of the major elevation peak over
the sampling interval in many cases (e.g., Figure 2D). Arbitrarily
summing the profile parameters further enhanced discrimination
(p,0.0006), giving 90% positive and negative predictive values for
6-month outcome using a cut point of 50. Age and gender did not
influence the results (p.0.35 for all comparisons).
Discussion
To our knowledge, these data are the first to link hypoxia with
acute elevations in serum Ab42 levels in living humans. These data
corroborate earlier results from animal models, which all suggest a
direct relationship between hypoxia and up-regulated amyloido-
genic APP-processing [7,8,9]. While we make no claim of the
observed changes being brain-specific, the data show that
circulatory failure with hypoxia dramatically increases Ab42 levels
in blood. Induced Ab42 production due to hypoxia appears to be
the most likely explanation for the results, but increased release
from cerebral tissues due to blood-brain barrier breakdown or
reduced clearance of the peptide cannot be excluded. The
magnitude of the increase is associated with clinical outcome,
which in turn probably reflects the severity of the ischemic episode.
A limitation of the study is the lack of a control group. However,
earlier results show that the day-to-day variability in Ab42 levels
normally is very low [17]. Moreover, the association of the SiMoA
Ab42 results with clinical outcome suggests a direct relationship
between the ischemic episode and Ab42 levels which is not
secondary to the standardized treatment all patients received.
Although there are many differences between acute hypoxia due
to cardiac arrest and age-related changes in the cerebrovascu-
lature, it is tempting to speculate that hypoxia induced by
arteriolosclerosis and/or lipohyalinosis may play a role in AD
pathogenesis by a direct effect on Ab levels in the brain. On top of
this, lowering of pH in hypoxic tissues would further stimulate Ab
oligomerization and aggregation as readily observed in the test
tube [18,19,20]. A direct effect of hypoxia on Ab production may
provide a putative mechanism for the mounting evidence from
Figure 3. Features of Ab42 elevation profiles were compared with 6-month overall cerebral outcome. (A) Magnitude of Ab42 rise; (B)
ratio of maximum to baseline Ab42; (C) duration of major Ab42 rise; (D) sum of A to C plus maximum slope of Ab42 rise. Error bars are the standard
error of the means.
doi:10.1371/journal.pone.0028263.g003
Hypoxia and Amyloid b Levels
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28263epidemiological studies linking cerebrovascular risk factors with
AD [3,4,5,6]. It may also help to explain the recently described
association of sleep apnea-induced hypoxia with dementia [21].
The data indicate that the SiMoA Ab42 assay represents a
breakthrough in analytical capability for extremely sensitive and
reproducible Ab42 measurement in serum and plasma. The assay
allows highly sensitive (limit of quantification 0.032 pg/mL) and
precise quantification of Ab42 in biological fluids. Current
immunoassays for measurement of Ab42 in plasma are based on
the ELISA [22,23,24] or the Luminex [25] techniques. In addition
to lower analytical sensitivity, these immunoassays are hampered
by low recovery of spiked Ab42 into plasma or serum, and as a
result the measured concentration of Ab42 increases when the
plasma sample is diluted [25]. These phenomena are due to matrix
effects, probably by interaction and binding of Ab42 to plasma
proteins. This means that unrelated plasma proteins contribute to
the concentration interpreted to come from Ab42 in this type of
assay. The immunoassay presented here showed highly linear
dilution characteristics, together with a recovery of around 100%,
suggesting that it gives a very accurate measure of the Ab42
concentration. This is likely because the interference from plasma
proteins is lost when samples are pre-diluted 1:4 prior to
measurement. Because the assay has such high sensitivity, pre-
diluting the samples does not compromise the capability of the
method to precisely measure low abundance Ab42. A highly
accurate and specific assay for measurement of Ab42 in blood will
be of major importance both for pathogenic studies on AD disease
mechanisms, and to monitor an effect on Ab metabolism of novel
therapeutic compounds in clinical trials, a hypothesis that will be
tested in future studies.
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